e20 Monoclonal Antibody Fragment for Broad HCV Genotype Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and immunotherapies for Hepatitis C virus (HCV) infections are ineffective due to the high variability of the virus's antigenic structure, particularly in neutralizing multiple genotypes, and existing antibodies like e20 are unable to neutralize viral infections even at high concentrations.
Innovation Solution
A monoclonal antibody fragment, e20, generated from a natural HCV genotype 1b infection, is capable of binding and neutralizing HCV glycoproteins from all known genotypes, with essential amino acid residues that inhibit viral replication, and is used as a medicament for therapeutic treatment and prevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies like e20 are used to neutralize HCV, then high neutralization activity against specific genotypes is achieved, but the ability to neutralize multiple genotypes (cross-reactivity) is insufficient
Solution Approach 1:
The patent applies universality by engineering the e20 antibody fragment to recognize and neutralize multiple HCV genotypes (1a, 1b, 2a, 2b, 3, 4, 5, and 6) through a single antibody structure. The modified e20 fragment achieves broad-spectrum neutralization activity across all known HCV genotypes while maintaining high potency, transforming a genotype-specific antibody into a universal anti-HCV therapeutic agent
2Quantity of substance
If high concentrations of e20 antibody fragment are used, then neutralization of viral binding is improved, but the ability to neutralize actual viral infection remains insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of the e20 antibody fragment through site-directed mutagenesis, specifically optimizing amino acid residues in the complementarity-determining regions (CDRs). These structural parameter changes enhance the antibody's affinity and neutralization mechanism, enabling effective infection neutralization at lower concentrations rather than relying on high dosage
3Ease of manufacture
If alpha interferon with ribavirin therapy is used, then treatment is provided for HCV infections, but response rate varies significantly by genotype
Solution Approach 1:
The patent introduces the engineered e20 antibody fragment as an intermediary therapeutic agent that mediates neutralization of HCV infection across all genotypes. Unlike genotype-dependent interferon therapy, this antibody serves as a universal mediator that binds to conserved epitopes on HCV E2 glycoprotein, providing genotype-independent neutralization and eliminating the need for genotype-specific treatment selection
Data Source
Figure 1
Figure 2a~2f
Figure 3
AI summary
The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes Ia, Ib, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.